JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2006; 47:1356-1360, doi:10.1016/j.jacc.2005.05.102 (Published online 14 March 2006).
© 2006 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (22)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ong, A. T.L.
Right arrow Articles by Serruys, P. W.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ong, A. T.L.
Right arrow Articles by Serruys, P. W.

Sirolimus-Eluting Stents Remain Superior to Bare-Metal Stents at Two Years

Medium-Term Results From the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) Registry

Andrew T.L. Ong, MBBS, FRACP, Ron T. van Domburg, PhD, Jiro Aoki, MD, Karel Sonnenschein, Pedro A. Lemos, MD, PhD and Patrick W. Serruys, MD, PhD, FACC*

Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands.


Figure 1
View larger version (17K):

[in a new window]
  		Figure 1 Two-year adverse events in patients treated with bare stents before the introduction of sirolimus-eluting stents (SES) (pre-SES group) and in patients treated exclusively with SES implantation (SES group). (A) Cumulative risk of death. (B) Death or myocardial infarction. (C) Death, myocardial infarction, or target vessel revascularization.

 

Figure 2
View larger version (18K):

[in a new window]
  		Figure 2 Two-year cumulative risk of target vessel revascularization in patients treated with bare stents before the introduction of sirolimus-eluting stents (SES) (pre-SES group) and in patients treated exclusively with SES implantation (SES group).

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2006 by the American College of Cardiology Foundation.